Consultation to reduce medication side effects using genetic information
Official title: Evaluating the Effectiveness of a Personalized Therapeutics Clinic (PTC) Intervention on Drug-Drug Interactions (DDIs) and Drug-Gene Interactions (DGIs)
Run by University of Chicago · NCT05166694 · Data updated 2026-11-12
This study is testing if a personalized clinic can help adults taking multiple medications by using their genetic information to reduce side effects and improve how their medicines work.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1300 (estimated) |
| Sponsor | University of Chicago Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Status | Recruiting |
| Started | November 30, 2022 |
| Main results expected | November 1, 2027 |
| Study ends | November 1, 2027 |
| Registry record updated | March 4, 2026 |
| Trial ID | NCT05166694 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who are prescribed five or more medications and are taking drugs with actionable pharmacogenomic information.
✕Probably not a fit
Patients who have undergone liver or kidney transplantation or those who have previously received genotyping from another source may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of a Personalized Therapeutics Clinic (PTC) in helping patients manage drug-drug and drug-gene interactions. Participants will undergo genetic testing to identify variations that may affect their response to medications, aiming to improve prescribing decisions and reduce side effects. The study will involve adult patients prescribed multiple medications and will last approximately nine months. The PTC will provide tailored advice based on genetic insights to enhance medication safety and efficacy.
Why it matters
Potential benefit: If successful, this approach could significantly reduce medication-related side effects and improve treatment outcomes for patients with complex medication regimens.
How similar studies have gone: Other studies have shown promise in using pharmacogenomic information to guide medication management, indicating that this approach may be beneficial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult participants cared for by a participating provider at University of Chicago Medical Center. 2. Participants must be at least 18 years of age. 3. Participants prescribed 5 or medication medications and taking a perpetrator drug or a drug with actionable pharmacogenomic information. Exclusion Criteria for Participants 1. Participants who have undergone, or are being actively considered for, liver or kidney transplantation. 2. Participation in another pharmacogenomic study. 3. Participants who have previously received genotyping from another source. 4. Inability to understand and give informed consent to participate. Inclusion of Women, Minorities, and Other Underrepresented Populations Individuals of all races and ethnic groups and genders are eligible for this trial.
Where it's running
-
University of Chicago Medicine
Chicago, Illinois, United States Recruiting
Study contacts
- Principal investigator: Mark Ratain, MD — University of Chicago
- Study coordinator: Andre Hall
- Email: andrehall@bsd.uchicago.edu
- Phone: (773)834-0936
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treatment of metastatic solid tumors with SLV-154
This study is testing a new treatment called SLV-154 for people with advanced solid tumors, like certain types of lung and breast cancer, to see how safe it is and how well it works.
-
Evaluating ALK202 for advanced solid tumors
This study is testing a new drug called ALK202 to see if it is safe and effective for adults with advanced solid tumors.
-
Oral Alintegimod with Ipilimumab followed by Nivolumab for advanced cancer
This study is testing if a new oral medication called Alintegimod, combined with two other cancer treatments, can help people with advanced solid tumors feel better and live longer.
-
Testing MGC026 in patients with advanced solid tumors
This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.
-
Evaluating CJRB-101 with Pembrolizumab for Advanced Cancer
This study is testing a new treatment combining CJRB-101 with pembrolizumab to see if it helps people with advanced cancers like lung cancer and melanoma feel better and respond better to their treatment.
-
Testing BIO-106 with pembrolizumab in patients with advanced cancers
This study is testing a new treatment called BIO-106, both alone and with pembrolizumab, to see if it can help people with advanced cancers that haven't responded to other therapies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.